New CAR t therapy targets tough lung cancers in first human trial
NCT ID NCT07488923
First seen Mar 28, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This early-phase study tests a new treatment called ML261 for people with small cell lung cancer or certain neuroendocrine cancers that have come back or stopped responding to standard therapy. ML261 uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to check safety and find the right dose, while also looking at whether the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Contact
-
NYU Langone Health
New York, New York, 10016, United States
Contact
-
Sarah Cannon Research Institute (SCRI)
Nashville, Tennessee, 37203, United States
Contact
Conditions
Explore the condition pages connected to this study.